Literature DB >> 28202211

The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.

E Stoeckle1, A Michot2, L Rigal3, F Babre4, P Sargos5, B Henriques de Figueiredo5, V Brouste6, A Italiano7, M Toulmonde7, F Le Loarer8, M Kind9.   

Abstract

BACKGROUND AND OBJECTIVES: Conservative surgery for soft-tissue sarcoma (STS) within multimodality treatment attempts to reconcile two contradictory requirements: assuring a good oncological outcome through a wide resection and preserving the function. The aim of our study is to verify whether our conservative approach to STS met these objectives.
METHODS: A retrospective database analysis was performed in adults with primary limb or trunk wall STS operated in a single center from 1989 to 2012. Predictive factors for postoperative complications and functional impairment were tested in a multivariate analysis.
RESULTS: 728 patients were operated (resection R0: 68%). Neoadjuvant chemotherapy (NAC) was given to 28%, postoperative radiotherapy to 70% of patients. Median follow-up was 103 months. At five years, overall survival was 80% and local recurrences 11%. Major postoperative complications occurred in 8% and functional impairment in 13% of the patients. Independent predictive factors for postoperative complications were American Society of Anesthesiologist classes 2 and 3 (OR: 2.3, CI: 1.2-4.5 and 4.0 CI: 1.7-9.3), tumor size >80 mm (OR: 2.5, CI: 1.3-4.9), tumor site (trunk wall/lower limb, OR: 4.1, CI: 1.3-13.6) and multifocal/multicompartmental spread (OR: 2, CI: 1.1-3.6). Independent predictive factors for function impairment were postoperative complications (OR: 5.3, CI: 2.8-10.1), NAC (OR: 3.6, CI: 2.2-5.8), and bone or neurovascular involvement (OR 3.3, CI 2.0-5.3), whereas Early Rehabilitation after Surgery (ERAS) improved outcome (OR: 0.5, CI: 0.3-0.9).
CONCLUSION: Postoperative complications induced functional impairment. They may be reduced by acting on comorbidity factors and careful tumor evaluation prior to surgery. Furthermore, ERAS measures improved function.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Enhanced recovery after surgery; Functional outcome; Morbidity; Multimodal treatment; Soft-tissue sarcoma; Surgery

Mesh:

Substances:

Year:  2017        PMID: 28202211     DOI: 10.1016/j.ejso.2017.01.018

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Enhanced recovery after surgery pathway in patients with soft tissue sarcoma.

Authors:  H G Lyu; L V Saadat; M M Bertagnolli; J Wang; E H Baldini; M Stopfkuchen-Evans; R Bleday; C P Raut
Journal:  Br J Surg       Date:  2020-07-03       Impact factor: 6.939

2.  Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma.

Authors:  Meena Bedi; Reena Singh; John A Charlson; Tracy Kelly; Candice Johnstone; Adam Wooldridge; Donald A Hackbarth; Nicole Moore; John C Neilson; David M King
Journal:  Adv Radiat Oncol       Date:  2022-01-25

3.  Functional Outcome Measurement in Patients with Lower-Extremity Soft Tissue Sarcoma: A Systematic Literature Review.

Authors:  Gilber Kask; Ian Barner-Rasmussen; Jussi Petteri Repo; Magnus Kjäldman; Kaarel Kilk; Carl Blomqvist; Erkki Juhani Tukiainen
Journal:  Ann Surg Oncol       Date:  2019-08-12       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.